Odyssey Therapeutics to Present Data for Three Immunology Programs at American College of Rheumatology Convergence 2023
09 Nov 2023
ImmunotherapyClinical StudyAACR
BOSTON--(BUSINESS WIRE)-- Odyssey Therapeutics, Inc., a biotechnology company pioneering next-generation precision immunomodulators and oncology medicines, will present data highlighting three of its immunology programs at the American College of Rheumatology (ACR) Convergence 2023 meeting in San Diego, California, November 10-15, 2023.
Odyssey’s oral and poster presentations will unveil the first public data for three novel therapeutic approaches to treat large populations with underserved inflammatory and autoimmune diseases. The receptor interacting protein kinase 2 (RIPK2) and interleukin-1 receptor-associated kinase 4 (IRAK4) scaffolding inhibitors, as well as tumor necrosis factor receptor-2 (TNFR2) agonist for regulatory T (Treg) cell modulation, represent targets and approaches of high interest in the pharmaceutical industry, given their broad potential to treat inflammatory disease.
“Odyssey’s team of expert drug hunters are tirelessly working to pioneer groundbreaking therapeutic strategies for the management of autoimmune disease,” said Gary D. Glick, Ph.D., founder and CEO of Odyssey Therapeutics. “At ACR, we’ll give patients, researchers and investors the first look at our RIPK2 and IRAK4 scaffolding inhibitorsIRAK4 scaffolding inhibitors, as well as TNFR2 agonist for Treg cell modulation. These therapies can offer transformative benefits for patients, and the findings shared at ACR reflect significant scientific progress and achievement by our team to understand and solve complex biology with small molecule and protein therapeutics.”
Oral Presentation
Title: Discovery of First-in-Class IRAK4 Scaffolding InhibitorsIRAK4 Scaffolding Inhibitors for the Treatment of Inflammatory Disorders
Abstract number: 2505
Session type: Abstract Session
Date and time: Tuesday, November 14, from 4-5:30 p.m. PST
Poster Presentations
Title: Discovery of a RIPK2 Scaffolding Inhibitor for the Treatment of Joint Autoimmune Diseases
Abstract number: 0061
Session type: Poster Session A
Date and time: Sunday, November 12, from 9-11 a.m. PST
Title: Anti-TNFR2 VHH Agonistic AntibodiesTNFR2 VHH Agonistic Antibodies Promote and Stabilize Treg Immunosuppressive Activity
Abstract number: 0068
Session type: Poster Session A
Date and time: Sunday, November 12, from 9-11 a.m. PST
About Odyssey Therapeutics
Odyssey Therapeutics is a biotechnology company focused on discovering, developing and commercializing the next generation of immunomodulators and oncology medicines. Composed of an expert team of drug hunters, scientists and industry leaders in foundational biology, chemistry and data sciences, Odyssey is transforming drug discovery to accelerate and drive the creation and efficient delivery of life-enhancing precision medicines to patients. For more information, please visit odysseytx.com and follow Odyssey Therapeutics on X (formerly Twitter) and LinkedIn.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.